We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
DBI, the expert in Molecular Breath Analysis applying artificial intelligence (AI) for state-of-the-art data interpretation announced today a collaboration with Bayer AG in the SPRAY-SMART study of a new nasal drug for OSAS.
A systematic review of studies by researchers at the University of Warwick has found that people who have been diagnosed with obstructive sleep apnoea could be at an increased risk of adverse outcomes from COVID-19.